Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMTI 
Rockwell Medical Inc (RMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: RMTI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.29% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.78M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 1.83 | 52 Weeks Range 0.78 - 5.15 | Updated Date 09/14/2025 |
52 Weeks Range 0.78 - 5.15 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.39% | Operating Margin (TTM) -8.39% |
Management Effectiveness
Return on Assets (TTM) -1.53% | Return on Equity (TTM) -7.79% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 51362170 | Price to Sales(TTM) 0.63 |
Enterprise Value 51362170 | Price to Sales(TTM) 0.63 | ||
Enterprise Value to Revenue 0.58 | Enterprise Value to EBITDA 41.66 | Shares Outstanding 34430400 | Shares Floating 28266630 |
Shares Outstanding 34430400 | Shares Floating 28266630 | ||
Percent Insiders 13.71 | Percent Institutions 17.19 |
Upturn AI SWOT
Rockwell Medical Inc
Company Overview
History and Background
Rockwell Medical, Inc. was founded in 1996. It is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company's focus has evolved from providing hemodialysis concentrates to developing and commercializing therapeutics.
Core Business Areas
- Therapeutics: Development and commercialization of therapeutics for ESRD and CKD patients, including Triferic, an iron maintenance therapy.
Leadership and Structure
Rockwell Medical is led by a management team overseeing its strategic direction. Specific details of the current leadership team can be found on their investor relations page. The company structure typically includes departments for research and development, manufacturing, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Triferic: Triferic is Rockwell Medical's primary product, indicated for iron maintenance in hemodialysis patients. It works by delivering iron to the bone marrow during dialysis, helping to maintain hemoglobin levels and reduce the need for IV iron supplementation. Competitors include traditional IV iron products from companies like Vifor Pharma and American Regent.
Market Dynamics
Industry Overview
The ESRD and CKD market is driven by the increasing prevalence of kidney disease, an aging population, and the demand for effective therapies. The market includes dialysis services, pharmaceuticals, and medical devices.
Positioning
Rockwell Medical positions itself as an innovator in the ESRD/CKD space with Triferic. Their advantage lies in its unique mechanism of action for iron maintenance during dialysis.
Total Addressable Market (TAM)
The TAM for iron replacement therapy in dialysis patients is estimated to be in the hundreds of millions of dollars annually. Rockwell Medical's positioning with Triferic aims to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Innovative product (Triferic)
- Targeted therapy for ESRD/CKD
- Potential to reduce IV iron use
Weaknesses
- Limited product portfolio
- Reliance on a single key product
- Commercial execution
Opportunities
- Expanding Triferic market share
- Developing new indications for Triferic
- Strategic partnerships and acquisitions
Threats
- Competition from established pharmaceutical companies
- Reimbursement challenges
- Clinical trial failures
- Generic competition
Competitors and Market Share
Key Competitors
- VIFOR (VIFN.SW)
- AMAG
- Fresenius (FMS)
Competitive Landscape
Rockwell Medical faces competition from larger pharmaceutical companies with broader product portfolios. Its advantage lies in the unique attributes of Triferic.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends can be evaluated based on past revenue growth, market share gains, and product adoption rates.
Future Projections: Analyst estimates for future revenue growth, EPS, and profitability should be reviewed to assess the company's future prospects.
Recent Initiatives: Focus on recent product launches, clinical trial results, and partnership announcements.
Summary
Rockwell Medical has a unique product with Triferic, but it faces challenges related to commercialization and competition. Its success depends on expanding Triferic's market share and potentially diversifying its product portfolio. The company needs to carefully manage its financial resources and navigate reimbursement hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Press releases
- Rockwell Medical Investor Relations website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rockwell Medical Inc
Exchange NASDAQ | Headquaters Wixom, MI, United States | ||
IPO Launch date 1998-01-27 | President, CEO & Director Dr. Mark Strobeck Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 244 | Website https://www.rockwellmed.com |
Full time employees 244 | Website https://www.rockwellmed.com | ||
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.